Szydlak Renata
Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kraków 31-034, Poland.
World J Stem Cells. 2023 Feb 26;15(2):16-30. doi: 10.4252/wjsc.v15.i2.16.
Diseases caused by ischemia are one of the leading causes of death in the world. Current therapies for treating acute myocardial infarction, ischemic stroke, and critical limb ischemia do not complete recovery. Regenerative therapies opens new therapeutic strategy in the treatment of ischemic disorders. Mesenchymal stem cells (MSCs) are the most promising option in the field of cell-based therapies, due to their secretory and immunomodulatory abilities, that contribute to ease inflammation and promote the regeneration of damaged tissues. This review presents the current knowledge of the mechanisms of action of MSCs and their therapeutic effects in the treatment of ischemic diseases, described on the basis of data from experiments and preclinical animal studies, and also summarize the effects of using these cells in clinical trial settings. Since the obtained therapeutic benefits are not always satisfactory, approaches aimed at enhancing the effect of MSCs in regenerative therapies are presented at the end.
缺血性疾病是全球主要死因之一。目前用于治疗急性心肌梗死、缺血性中风和严重肢体缺血的疗法无法实现完全康复。再生疗法为缺血性疾病的治疗开辟了新的治疗策略。间充质干细胞（MSCs）是细胞疗法领域最有前景的选择，因其具有分泌和免疫调节能力，有助于减轻炎症并促进受损组织的再生。本综述基于实验和临床前动物研究的数据，介绍了目前关于间充质干细胞作用机制及其在缺血性疾病治疗中的治疗效果的知识，并总结了这些细胞在临床试验中的应用效果。由于所获得的治疗益处并不总是令人满意，最后还介绍了旨在增强间充质干细胞在再生疗法中效果的方法。
